{
  "docId": "019de074-559c-76fa-9457-a7d91e9a06c5",
  "docSlug": "15199f0b497c4ef204a0760da27401b3",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 54 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 36,
  "pageCount": 54,
  "prevPage": 35,
  "nextPage": 37,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 15,
  "notes": "Includes a table of pharmacokinetic parameters and a line chart showing plasma concentration over time.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-559c-76fa-9457-a7d91e9a06c5/36",
  "deckHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5",
  "deckJsonHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5.json",
  "deckAnchorHref": "/decks/019de074-559c-76fa-9457-a7d91e9a06c5#slide-36",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.43,
        "x": 0.53,
        "y": 0.515
      },
      "kind": "chart",
      "text": "Mean Plasma Concentration Time Profile of 3 Topical Sildenafil Doses",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43098a8b-e57c-4b9c-b610-3402c13ef893",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.04,
        "y": 0.615
      },
      "kind": "paragraph",
      "text": "Phase 2a Study of SST-6007(Sildenafil Cream, 3.6%)\nDemonstrated increased blood flow in the genital tissue compared to placebo (mean change in VPA analysis) in 31 women (pre and postmenopausal) ~30 minutes post dosing.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "535a95c7-46b9-423c-a8b0-80f624aacfaa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.04,
        "y": 0.265
      },
      "kind": "paragraph",
      "text": "Phase 1 Study of SST-6007 (Sildenafil Cream, 3.6%)\nNormal healthy postmenopausal women were dosed with escalating doses of Sildenafil Cream, 3.6%, using a cross-over study design.\nSildenafil Cream had significantly lower systemic exposure compared to a 50 mg oral sildenafil dose\nAUC - 3-6%\nCmax - 1-2%\nSildenafil Cream was safe and well tolerated at clinically relevant doses (1-2g)\nFavorable product characteristics as self-reported by subjects\nEasy to use\nReadily absorbed",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5dc188fe-3beb-43ed-a090-9a39c271573c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.35,
        "x": 0.04,
        "y": 0.815
      },
      "kind": "source-note",
      "text": "1. Data on file. Sildenafil Cream, 3.6% was previously known as SST-6007.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0c791e4c-325b-49f0-a762-bd219e501351",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.43,
        "x": 0.53,
        "y": 0.285
      },
      "kind": "table",
      "text": "Parameter | 1 g cream | 2 g cream | 4 g cream\nCmax (ng/mL) | 3.61 | 4.10 | 5.65\nAUCo-t(h*ng/mL) | 27.45 | 33.32 | 45.33\nTmax (hr) | 2.56 | 2.60 | 2.42",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a97d7870-eca9-4aca-bd50-35805936eb65",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.72,
        "x": 0.14,
        "y": 0.15
      },
      "kind": "title",
      "text": "Sildenafil Cream, 3.6% - Phase 1 and Phase 2a Study Results",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e95f8aa8-3b6d-4a81-a6ff-368b6352f3c2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 54,
      "from": 17,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "2cf418f8-2568-4e9a-bf9d-f55bdd0bfb9e",
      "evidence": "The deck implies that inaction in women's health has significant consequences",
      "position": 0,
      "objective": "What is the cost of inaction in women's health?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}